Table 4 Within-group analysis of NLR, PLR, and PNI before and after treatment
From: Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
Group | Â | Baselines, M (IQR) | Post-treatment, M (IQR) | p |
|---|---|---|---|---|
Within the TD subgroup | NLR | 2.77 (2.04–4.33) | 2.77 (2.40–4.80) | 0.451 |
PLR | 162 (125.26–244.00) | 159.44 (102.51–237.31) | 0.791 | |
PNI | 48.1 (44.30–52.70) | 49.55 (45.55–52.84) | 0.353 | |
Within the Non-TD subgroup | NLR | 3.20 (2.25–4.78) | 3.02 (1.98–4.04) | 0.042 |
PLR | 160.70 (110.79–219.89) | 152.16 (112.98–208.02) | 0.774 | |
PNI | 48.15 (43.175–52.25) | 48.03 (45.92–51.52) | 0.829 |